Opendata, web and dolomites

BETASCREEN

A Unique Pancreatic Human Beta Cells to revolutionize the Diabetes Drug Discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BETASCREEN project word cloud

Explore the words cloud of the BETASCREEN project. It provides you a very rough idea of what is the project "BETASCREEN" about.

surprise    saving    coherence    issue    creation    pressure    attrition    division    poor    reproducibility    company    academia    commercialization    clinical    drug    bottlenecks    turnover    human    ub    technologies    world    think    prevents    dollars    first    rentability    accelerate    predictability    marketed    cells    15    million    population    lack    secure    commercial    tissues    lines    animal    leaders    maturity    solution    hope    substitute    generation    industrial    avenues    regulatory    cell    disruptive    accessible    predictive    screening    replication    strategy    scarce    1billion    ing    110    anti    leader    decreasing    says    betascreen    types    edge    univercell    homogeneity    industry    overcome    selling    ultimate    adoption    revenues    biotech    tornell    patients    portfolio    10    diabetes    generating    segments    line    cutting    90    stem    astrazeneca    beta    2015    2021    industrials    faced    pharma    big    biosolutions    quantity    pancreatic    exceptional    pharmaceutical    pharmas    pioneering    samples    innovative    rate    outcome    market    jobs    strategic    models    europe    jan   

Project "BETASCREEN" data sheet

The following table provides information about the project.

Coordinator
UNIVERCELL BIOSOLUTIONS SAS 

Organization address
address: PLACE PIERRE POTIER CENTRE PIERRE POTIER CANCEROPOLE ENTREE B
city: TOULOUSE
postcode: 31000
website: www.univercell-biosolutions.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.endocells.com/products-and-services/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERCELL BIOSOLUTIONS SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Univercell Biosolutions (UB) is a pioneering biotech company providing unique human cell models to accelerate and secure pharmaceutical products. UB is generating 1 M€ turnover in 2015 selling its first generation of human beta cell lines to 10 world pharma industry leaders. Pharmas rentability is decreasing facing to high regulatory pressure and low clinical predictability on human. The rate of clinical drug failure is about 90% and cost for marketed a new drug reach up to 1billion dollars. Early clinical predictability is a strategic issue for industrials. Jan Tornell an AstraZeneca division leader says: “The big think is that when we get into patients, we want no surprise”. Cells from human tissues samples are scarce and not accessible for Pharmas applications. Thus, Industrials developed substitute from animal with poor clinical predictability. Recently, Stem cell technologies has open new hope in providing large quantity of human cells but is still faced with major bottlenecks: lack of cell maturity (clinical predictability) and low cell population homogeneity (reproducibility) which prevents large adoption by industrials. UB has developed a portfolio of cutting edge technologies to overcome these bottlenecks. The first outcome of BETASCREEN is a disruptive pancreatic beta cell line for anti-diabetes research, with ultimate objective of replication to other cell types. The solution targets pharmaceutical, biotech, and academia. Within BETASCREEN, UB will define best commercialization strategy in coherence with market’s targeted segments and identify industrial partners for large-scale production (Phase 2) and commercialization. BETASCREEN will improve the predictive value of screening by decreasing the drug attrition rate up to 10%. Resulting cost saving for industrials could reach 100 million dollars per innovative new drug development. This will open exceptional commercial avenues for UB with revenues estimated at 15 M€ in 2021 and 110 jobs creation in Europe

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETASCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETASCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MyPal (2019)

MyPal: Fostering Palliative Care of Adults and Children with Cancer through Advanced Patient Reported Outcome Systems

Read More  

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

HEADSpAcE (2019)

Translational studies of HEAD and neck cancer in South America and Europe

Read More